Pentair Jumps 18% as Analysts Reverse Course After Earnings
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
PNR has staged one of its sharpest weekly rallies in recent memory, up 18% to $62.29, with the Street now scrambling to revise targets it spent two weeks cutting.
A week ago, the picture looked grim. Analysts had spent October slashing price objectives across the board, with Goldman Sachs, RBC, Mizuho, Citigroup and Oppenheimer all trimming targets while keeping ratings intact. The previous note here captured that tension precisely: a Street consensus pointing to 34% upside from $52.88, undercut by the fact that every firm had just moved its own number lower. That contradiction has now partly resolved itself. PNR reported Q3 results on October 27, and the market's response was decisive. The stock gained nearly 13% on the day alone. Since then, two fresh analyst actions have arrived. RBC raised its target to $69 from $61 while keeping its Sector Perform rating, and BNP Paribas upgraded the stock outright to Neutral from Underperform with a $65 target. Both moves are post-results recalibrations. The consensus now rests at $73.60, implying roughly 18% further upside from current levels.
Positioning tells a quiet story behind the surge. Short interest is modest at 4.5% of the free float, down about 1% on the week and down nearly 15% over the past month. Borrowing costs are low and falling, at 0.38%, down 23% on the week. Availability in the lending market is extremely loose, currently running at 2,739%, meaning shares available to borrow dwarf the existing short position by a wide margin. That rules out any short-squeeze mechanics as an explanation for this week's move. The rally is driven by fundamentals and positioning rotation, not forced covering. Options confirm the calm. The put/call ratio is 0.58, fractionally below its 20-day average of 0.60, and the z-score of minus 0.45 shows no unusual skew in either direction. The ORTEX short score has nudged down to 36.9 from a recent peak around 39.4, consistent with short sellers retreating rather than pressing.
The bull and bear cases are now in sharper relief after the print. Bulls point to Pool segment sales up 11.2% year-over-year and Flow revenue up 9.3%, with the company projecting mid-to-high single-digit revenue growth for 2026 alongside 100 basis points of margin expansion. Bears counter that the Water Solutions segment fell 9.9% year-over-year, commercial sales dropped 15%, and the demand picture for the pool business remains fragile heading into 2026. Valuation has re-rated quickly. The P/E multiple is now 12.1, up 1.75 points on the week, and EV/EBITDA has jumped nearly a full turn to 9.6. PNR scores well on earnings yield (72nd percentile) and EV/EBIT (76th percentile), and the analyst recommendation differential factor ranks in the 97th percentile, a reflection of how far consensus leans positive relative to how the stock has traded. One data point worth noting: retail attention, as measured by Wikipedia page views and ORTEX stock page traffic, has jumped to a z-score of 3.5 against PNR's own 90-day history. That is a sharp spike in public interest and is consistent with a name that just moved 13% in a day.
On the ownership register, BlackRock filed a fresh Schedule 13G/A on October 27, disclosing its stake has fallen to 6.9% from a prior 9.0%. That is a meaningful reduction from the largest holder, though the filing is an event-driven disclosure around the 5% threshold and the current position per the institutional holdings table still shows 14.5 million shares as of September 30. The divergence between the 13G/A disclosure and the holdings table reflects different reporting dates. T. Rowe Price similarly trimmed from 7.0% to 4.0% in its August filing. Insider activity is not a factor here: the only recent EDGAR-sourced transactions are a director award and routine tax-withholding sales from the interim CFO, none of them open-market trades.
The question heading into the next quarter is whether the Q3 earnings reaction marks a turning point or a relief trade. The most closely correlated US peer, XYL, fell 14% on the day and 12% on the week, a stark divergence that will draw attention. Analysts who held targets well above $60 through the selloff now face PNR trading close to those numbers. The next earnings date is February 2, 2027, 97 days away. Until then, the focus shifts to whether Q4 demand in Pool and Water Solutions stabilises, and whether the target compression that defined October fully reverses or stalls near current levels.
Stocks in this article
See the live data behind this article on ORTEX.
Open PNR on ORTEX →How this article was generated
- Generated
- 28 Oct 2026, 17:32
- Data as of
- 28 Oct 2026, 17:31
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.